EZH2 and acute myeloid leukemia: Our data showing that EZH2 inhibition greatly enhanced the genotoxic effect of the FDA approved PARP inhibitor olaparib on hemapoietic cells from AML patients support the proposed hypothesis of a role of EZH2 in DNA repair.